New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer
https://doi.org/10.17650/1726-9776-2019-15-3-89-101
Abstract
Currently, enzalutamide is the standard of pharmaceutical therapy of metastatic and non-metastatic castration-resistant prostate cancer. However, until recently there was no data on effectiveness and safety of enzalutamide in metastatic hormone-sensitive prostate cancer. Results of 2 large randomized clinical trials ARCHES and ENZAMET showed that early prescription of enzalutamide in combination with standard androgen deprivation therapy allows to significantly increase survival of patient with metastatic hormone-sensitive prostate cancer. The review describes data of these trials and advisability of prescribing enzalutamide in combination with androgen deprivation therapy as 1st line therapy of metastatic hormone-sensitive prostate cancer.
About the Author
B. Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Tannock I.F., de Wit R., Berry W.R. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502–12. DOI: 10.1056/NEJMoa040720.
2. Ryan C.J., Smith M.R., de Bono J.S. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 10;368(2):138–48.
3. Beer T.M., Armstrong A.J., Rathkopf D.E. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33. DOI: 10.1056/NEJMoa1405095.
4. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. DOI: 10.1056/NEJMoa1207506.
5. Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, doubleblind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983–92. DOI: 10.1016/S1470-2045(12)70379-0.
6. de Bono J.S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376(9747):1147–54. DOI: 10.1016/S0140-6736(10)61389-X.
7. Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. DOI: 10.1056/NEJMoa1213755.
8. Maximum androgen blockade in advanced prostate cancer: an overview of the randomized trials. Prostate Cancer Trialist’s Collaborative Group. Lancet 2000;355:1491–8.
9. Kyriakopoulos C.E., Chen Y.H., Carducci M.A. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 2018;36(11):1080–7. DOI: 10.1200/JCO.2017.75.3657.
10. James N.D., Sydes M.R., Clarke N.W. et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2016;387(10024):1163–77. DOI: 10.1016/S0140-6736(15)01037-5.
11. Fizazi K., Tran M.P., Fein L. et al. Abiraterone acetate and prednisone in patients with newly diagnosed high risk metastatic castrate-sensitive prostate cancer (LATTITUDE) final overall survival analysis of a randomized, double-blind, phase 3 trial. Lancet 2019;5:686–700.
12. James N.D., de Bono I.S., Spears M.R. et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 2017;377(4):338–51. DOI: 10.1056/NEJMoa1702900.
13. Hussain M., Fizazi K., Saad F. et al. Enzalutamide in men with nonmetastatic, castrate-resistant prostate cancer. N Engl J Med 2018;378:2465–74.
14. Armstrong A.J., Szmulewitz R.Z., Petrylak D.P. et al. ARCHES: a randomized phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 2019. DOI: 10.1200/JCO.19.00799.
15. Davis I.D., Martin A.J., Stockler M.R. et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med 2019;381(2):121–31. DOI: 10.1056/NEJMoa1903835.
Review
For citations:
Alekseev B.Ya. New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer. Cancer Urology. 2019;15(3):89-101. (In Russ.) https://doi.org/10.17650/1726-9776-2019-15-3-89-101
Views:
705
Email this article 